Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:vitamin_A |
| gptkbp:approvalYear |
1999
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX42
|
| gptkbp:brand |
gptkb:Targretin
|
| gptkbp:CASNumber |
153559-49-0
|
| gptkbp:developedBy |
gptkb:Ligand_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
7 hours
|
| gptkbp:hasMolecularFormula |
C24H28O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
bexarotene
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
retinoid X receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
99%
|
| gptkbp:PubChem_CID |
74113
82146 CHEMBL1202 DB00310 |
| gptkbp:routeOfAdministration |
oral
topical |
| gptkbp:sideEffect |
headache
hypothyroidism rash leukopenia hyperlipidemia |
| gptkbp:synonym |
LGD1069
|
| gptkbp:UNII |
YCD2M6V9V3
|
| gptkbp:usedFor |
leukemia
|
| gptkbp:bfsParent |
gptkb:RARA
gptkb:Targretin gptkb:retinoid_X_receptor_(RXR) |
| gptkbp:bfsLayer |
7
|